Biomedical Advanced Research and Development Authority (BARDA)
330 C Street, SW
Room G640
Washington
D.C.
20201
United States
Tel: 202-260-1200
Fax: 202-205-4520
159 articles with Biomedical Advanced Research and Development Authority (BARDA)
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
-
BARDA reselects ICON as preferred partner to help strengthen US emergency preparedness and response
10/19/2020
ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries and government and public health organisations, has been re-selected by the Biomedical Advanced Research and Development Authority (BARDA) to c
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.
-
In his resignation, Bright said that the Trump administration “ignores scientific expertise, overrules public health guidance and disrespects career scientists.”
-
Locus Biosciences signs contract with BARDA to advance $144 million precision medicine program to develop LBP-EC01, a crPhage™ product
9/30/2020
Locus Biosciences announced today that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) to co-fund development of LBP-EC01, a CRISPR Cas3-enhanced bacteriophage (crPhage™) product that will target Escherichia coli ( E. coli ) bacteria causing recurrent urinary tract infections
-
Esperovax Awarded New Contract With BARDA
9/23/2020
Esperovax, the leader in Egress RD™ Oral Biologics has been awarded $607,000 in funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Respons
-
Luminex Receives BARDA Award to Support Enhancement of COVID-19 Multiplex Antibody Test
9/23/2020
Project will expand utility of xMAP SARS-CoV-2 Multi-Antigen IgG Assay to better indicate whether individuals are protected against future infection [23-September-2020] AUSTIN, Texas , Sept. 23, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received an award of $683,500 from the Biomedical Advanced Research and Development Autho
-
Ortho Awarded BARDA Contract to Accelerate Antigen Test Development and Additional SARS-CoV-2 Antibody Test Milestones
9/21/2020
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced its continued collaboration with the Biomedical Advanced Research and Development Authority ( BARDA ), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, in a new contr
-
BARDA and NOWDiagnostics Partner to Develop Rapid COVID-19 Antibody Test for Use Point-of-Care and At-Home
8/31/2020
NOWDiagnostics, Inc. announced today it is working with BARDA, the Biomedical Advanced Research and Development Authority arm of the U.S. Department of Health and Human Services, to develop a serological test for SARS-CoV-2 antibodies that can be used across a variety of health care settings—from clinics to hospital emergency ro
-
The idea is to support companies that anticipate “potential health security threats, activating the global innovation community, and amplifying scientific and technological advances with the aim to prepare for and respond to our rapidly evolving global health environment.”
-
MediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid to BARDA for Emergency Response Preparedness
8/25/2020
MediWound Ltd. and its U.S. commercial partner Vericel Corporation announced that the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has accepted the first shipment of NexoBrid® as part of its mission to build national preparedness for public health emergencies.
-
Stéphane Bancel, Moderna’s chief executive officer, stated, “We thank BARDA for this continued commitment to mRNA-1273, our vaccine candidate against COVID-19."
-
Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19
7/26/2020
Additional funding to support expanded mRNA-1273 clinical development plan including 30,000 participant Phase 3 COVE study conducted in collaboration with the NIH
-
BARDA to Initiate Procurement of the RECELL® System for Emergency Response Preparedness
7/13/2020
AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that the Biomedical Advanced Research and Development Authority (BA
-
BD Partners with U.S. Government on $70 Million Manufacturing Infrastructure Project for Mass Vaccination Campaigns
7/8/2020
Company Finalizes Initial Pandemic Order for 50 Million Injection Devices to Support Operation Warp Speed Vaccination Program
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 8, 2020.
-
Regeneron Announces Manufacturing and Supply Agreement for BARDA and U.S. Department of Defense for REGN-COV2 Anti-Viral Antibody Cocktail
7/7/2020
Regeneron Pharmaceuticals, Inc. announced that, as part of Operation Warp Speed, the BARDA, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense have awarded Regeneron a $450 million contract to manufacture and supply REGN-COV2.
-
This deal with BARDA and the DoD supports continuing the manufacturing in order for it to be immediately available in the U.S. if the clinical trials are successful.
-
MBio Diagnostics and BARDA Partner on a 5-minute, Quantitative Point-of-Care COVID-19 Antibody Panel
6/23/2020
MBio Diagnostics announced it has been awarded a $629,595 contract from the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to develop and commercialize their point-of-care multiplex serology test for the detection of human anti-SARS-CoV-2 antibodies.
-
Empatica and BARDA Join Forces to Validate Wearable System That Detects COVID-19 Before Symptoms Appear
6/19/2020
Digital healthcare company Empatica announces a pioneering new partnership with the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Office of the